Peptide drugs are known for their high specificity, strong target affinity, and low risk of off-target effects. However, compared to small molecule drugs, they suffer from low oral bioavailability, poor plasma stability, and short circulation time. Optimizing these DMPK (Drug Metabolism and Pharmacokinetics) properties of peptides is crucial for their development. This webinar will explore essential strategies for optimizing the DMPK profiles of peptides, including the selection of appropriate in vitro matrices, tailored sample processing techniques, and leveraging WuXi AppTec’s extensive experience and study platforms. Attendees will gain insights into the key factors that influence peptide drug development, from early screening to IND-enabling studies.
Learning objectives:
Jianping Sun
Mr. Jianping Sun, graduated from the School of Life Sciences of Nanjing University, and joined WuXi AppTec in 2008. He currently serves as a senior leader in the DMPK Service Department’s Study Director team. He has five years of lab experience in in vitro ADME studies, ten years of experience in DMPK project management, and is proficient in global IND application strategies for new drugs. He has led the team to complete over 60 IND application projects, including various types of molecular entities such as small molecules, PROTAC, peptides, oligonucleotides, antibodies, ADC, etc.